Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-29
2008-07-29
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07405219
ABSTRACT:
The use of a compound of formula (I):whereinR1is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7and NR4SO2R7;R2is selected from aryl attached via an unsaturated carbon;R3is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6and SO2R7;R4, R5and R6are independently selected from H, alkyl and aryl or where R5and R6are in an NR5R6group, R5and R6may be linked to form a heterocyclic group, or where R4, R5and R6are in a (CONR4NR5R6) group, R4and R5may be linked to form a heterocyclic group; andR7is selected from alkyl and aryl,or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.
REFERENCES:
patent: 4739053 (1988-04-01), Albert et al.
patent: 5204353 (1993-04-01), Meier
patent: 5747496 (1998-05-01), Cox et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6197788 (2001-03-01), Fletcher et al.
patent: 6583156 (2003-06-01), Gillespie et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 1 221 444 (2002-07-01), None
patent: 1 300 147 (2003-04-01), None
patent: 56/131586 (1981-10-01), None
patent: 56/131587 (1981-10-01), None
patent: 59/062595 (1984-04-01), None
patent: 60/140335 (1985-07-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/21617 (1999-05-01), None
(Abstract only) Bailey et al., “Changes in spinal δ- and κ-opioid systems in mice deficient in the A2A receptor gene”,Journal of Neuroscience, vol. 22, No. 21, 2002 (pp. 9210-9220).
(Abstract only) Bara-Jimenez et al., “Adenosine A2A receptor antagonist treatment of Parkinson's disease”,Neurology, vol. 61, No. 3, 2003 (pp. 293-296).
Bastia et al., “Effects of A1and A2Aadenosine receptor ligands in mouse acute models of pain”,Neuroscience Letters 328, 2002 (pp. 241-244).
Behan et al., “Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2Areceptor antagonists”,British Hournal of Pharmacology, vol. 135, 2002 (pp. 1435-1442).
Bertorelli et al., “Effects of Selective Agonists and Antagonists for A1or A2AAdenosine Receptors on Sleep-Waking Patterns in Rats”,Drug Development Research, vol. 37, 1996 (pp. 65-72).
(Abstract only) Chase et al., “Translating A2Aantagonist KW6002 from animal models to parkinsonian patients”,Neurology, vol. 61, (11, Suppl. 6), (pp. S107-S111).
Dall'lgna et al., “Neuroprotection of caffeine and adenosine A2Areceptor blockade of β-amyloid neurotoxicity”,British Journal of Pharmacology, vol. 138, 2003 (pp. 1207-1209).
Fredholm, et al., “Actions of Caffeine in the Brain with Special References to Factor That Contribute to Its widespread Use”,Pharmacological Reviews, vol. 51, No. 1, 1999 (pp. 83-133).
Garfinkel, et al., “Responses to Methylphenidate and Varied Doses of Caffeine in Children with Attention Deficit Disorder”,Can. J. Psychiatry, vol. 26, No. 6, Oct. 1981 (pp. 395-401).
González-Benitez et al., “Regulation of glycogen metabolism in hepatocytes through adenosine receptors. Role of Ca2+and cAMP”,European Journal of Pharmacology, vol. 437, 2002 (pp. 105-111).
(Abstract only) Hauser et al., “Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD”,Neurology, vol. 61, No. 3, 2003 (pp. 297-303).
Hess, “Recent advances in adenosine receptor antagonist research”,Review, Monthly Focus: Central and Peripheral Nervous Systems, 2001 (pp. 1533-1561).
Ikeda et al., “Neuroprotection by adenosine A2Areceptor blockade in experimental models of Parkinson's disease”,Journal of Neurochemistry, vol. 80, No. 2, Jan. 2002 (pp. 262-270).
(Abstract only) Kase, “New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia”,Biochemistry, vol. 65, No. 7, 2001 (pp. 1447-1457).
Kopf et al., “Adenosine and memory storage: effect of A1and A2receptor antagonists”,Psychopharmacology, vol. 146, No. 2, Sep. 11, 1999 (pp. 214-219).
(Abstract only) Ledent et al., “Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor”,Nature, vol. 388(6643), Aug. 14, 1997 (pp. 674-678).
Li et al., “Differing Roles of Adenosine Receptor Subtypes in Retinal Ischemia-Reperfusion Injury in the Rat”,Exp. Eye Res., vol. 68, 1999 (pp. 9-17).
Mally et al., “Potential of Adenosine A2AReceptor Antagonists in the Treatment of Movement Disorders”,CNS Drugs, vol. 10, No. 5, Nov. 1998 (pp. 311-320).
Monopoli et al., “Blockade of adenosine A2Areceptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats”,Neuropharmacology, vol. 9, No. 17, Dec. 1, 1998 (pp. 3955-3959).
Monopoli et al., “Cardiovascular Pharmacology of the A2AAdenosine Receptor Antagonist, SCH 58261, in the Rat”,The Journal of Pharmacology and Experimental Therapeutics, vol. 285, No. 1, 1998 (pp. 9-15).
Ongini et al., “Dual Actions of A2AAdenosine Receptor Antagonists on Motor Dysfunction and Neurodegenerative Processes”,Drug Development Research, vol. 52, No. ½, 2001 (pp. 379-386).
Popoli et al., “Blockade of Striatal Adenosine A2AReceptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum”,The Journal of Neuroscience, vol. 22, No. 5, Mar. 1, 2002 (pp. 1967-1975).
Satoh et al., “Involvement of adenosine A2Areceptor in sleep promotion”,European Journal of Pharmacology, vol. 351, 1998 (pp. 155-162).
Scammell et al., “An Adenosine A2a Agonist Increases Sleep and Induces FOS in Ventrolateral Preoptic Neurons”,Neuroscience, vol. 107 No. 4, 2001 (pp. 653-663).
Schechter, M.D. et al., “Objectively Measured Hyperactivity—II. Caffeine and Amphetamine Effects”,J. Clin. Pharmacol., vol. 25, 1985 (pp. 276-280).
Stone et al., “Neuroprotection by A2AReceptor Antagonists”,Drug Development Research, vol. 52 No. ½, 2001 (pp. 323-330).
Svenningsson, P. et al., “Distribution, Biochemistry and Function of Striatal Adenosine A2AReceptors”,Progress in Neurobiology, vol. 59, 1999 (pp. 355-396).
(Abstract only) Urade et al., “Sleep regulation in adenosine A2Areceptor-deficient mice”,Neurology, vol. 61(11, Suppl. 6), 2003 (pp. S94-S96).
(Abstract only) Varani et al., “Aberrant A2Areceptor function in peripheral blood cells in Huntington's disease”,FASEB Journal, vol. 17, No. 14, 2003 (pp. 2148-2150).
Varani et al., “Adenosine A2AAntagonists and Huntington's disease”,Colloque Scientifique sur le Café,2001, 19th(pp. 51-58).
Ei Yacoubi et al., “Adenosine A2Areceptor antagonists are potential antidepressants: evidence based on pharmacology and A2Areceptor knockout mice”,British Journal of Pharmacology, vol. 134, No. 1, 2001 (pp. 68-77).
Betti, L. et al., “New amino derivatives of 1,2,3-triazolo′4,5-dlprimidines and their affinity towards A1 and A2A adenosine receptors,”European Journal of Medicinal Chemistry, Editions Scientifique(Oct. 1999), vol. 34, No. 10, Elseiver, Paris, France, pp. 867-875, XP004202941, ISSN: 0223-5234.
Cocuzza, A.J. et al., “Use of the suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) a
Bamford Samantha Jayne
Gaur Suneel
Gillespie Roger John
Leonardi Stefania
Lerpiniere Joanne
Coleman Brenda L.
Foley & Lardner LLP
Moore Susanna
Vernalis Research Limited
LandOfFree
Triazolo [4,5-d] pyrimidine derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolo [4,5-d] pyrimidine derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolo [4,5-d] pyrimidine derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814925